Dr Helen Townley, BSc, PhD
I am the William Dodd foundation Research Fellow, and lead a research group working on new and innovative therapies for childhood cancers.
My degree and PhD are in Biochemistry, and I have worked at the University of Oxford since 1998. I am now a University Research Lecturer, and a Senior Visiting Research Fellow in Engineering Sciences.
The fact that our research is supported by both the medical faculty and Engineering Sciences means that we are able to carry out interdisciplinary research ranging from nanoparticle synthesis and analysis through to cell culture and biological assays of materials.
My laboratory is based at the Begbroke Science Park in the Institute for Advanced Technology.
You can read more about my work here.
Karl Morten PhD, Principle Investigator,
A leading international mitochondrial researcher with extensive research experience developed at the University of Oxford and the Buck Institute for Aging Research (California). Career highlights include identifying novel mutations in mitochondrial disease, the utility of using dichloroacetate to increase the activity of pyruvate mutations, identification of high levels of tau phosphorylation in the SOD2 mutant mouse brain. This experience has established Dr Morten as one of the leading mitochondrial research experts in Europe. PI at University of Oxford since 2010 investigating the role of the mitochondria in diabetes, cancer, drug toxicity, neuronal drug action and ischaemia,
Dr. Morten is driving mitochondrial research at the University of Oxford where the Morten laboratory is at the hub of a mitochondrial research. In addition to establishing a collaborative mitochondrial biology research community through the founding and contented co-ordination of MitOX; an Oxford-based international meeting on mitochondrial biology and metabolism Dr. Morten also sits on the University of Oxford metabolism committee. Dr. Morten’s international reputation in mitochondrial research has led to interest from the pharmaceutical sector with current projects running with Bayer, Glaxo Smithkline and GW Pharmaceuticals.